• Skip to main content
  • Skip to footer

Histogen

  • About Us
  • Our Science
  • Investors
  • Contact
Home Hero

Immunotherapy. Redefined.

Who we are

Managed by highly successful biotech industry veterans, Histogen is a drug development company initially focused on treating infectious diseases by restoring the competence of the human body’s immune system to effectively combat these infections. Histogen is doing this by developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that help restore the body’s natural immune processes that are being attacked by invading organisms.

Our product candidates include emricasan, CTS-2090, and other proprietary caspase inhibitors. Currently, we are developing emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Our pipeline also includes novel preclinical product candidates including CTS-2090 which are highly selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases.

Who We Are Img
Our science

Game-changing
immunotherapy solutions

Learn more about our science Green Arrow Round

Icon 1

Non-antibiotic solution to prevent antibiotic resistanc

Icon 2

Tested, known pathway of approval and known endpoints

Icon 3

Inflammation suppression that may cure infections faster

Pipeline

Innovative solutions
to target immune systems

View our science

Emricasan

Emricasan is an orally available pan-caspase inhibitor that effectively reduces inflammation and disease-driven cell damage and death by a process known as apoptosis. Emricasan has been extensively studied in multiple clinical trials involving over 1000 subjects. Emricasan has been chronically dosed for up to 2 -years in immunosuppressed patients and found to be well tolerated. In preclinical models, Emricasan effectively eradicated MRSA bacterial skin infection by a novel host-mediated mechanism of action.

CTS-2090

CTS-2090 is a novel, orally available inhibitor of inflammatory caspases that potently inhibits the production of IL-1 and IL-18, both of which are clinically validated as important therapeutic targets. In preclinical studies, CTS-2090 has been shown to distribute to the colon and is highly effective in models of ulcerative colitis and has the potential to be beneficial in bacterial infections in the gastrointestinal tract such as clostridium difficile.

Emricasan
CTS-2090
  • Slider Left Arrow
  • Slider right Arrow
About Us

Working to bring
life-changing options to
redifine immumotherapy

Learn more about us Green Arrow Round

We are clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. Our product candidates include emricasan, CTS-2090 and other proprietary caspase inhibitors.

Updates and news

Gettyimages 1309707729 Green Arrow
20.04.2023

Histogen Announces Online Publication in the Journal of Investigative Dermatology

Covid 19 Blue Green Arrow
03.04.2023

Histogen Announces Exclusive Intellectual Property License Agreement with Johns Hopkins University

Close Up Of 3d Microscopic Blue Bacteria Green Arrow
16.03.2023

Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use

Information for investors

For investors

Logo V1

Contact us
858-526-3100
info@histogen.com

dashicons-twitter dashicons-linkedin

Privacy Policy | Web Accessibility | Site Map

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply

Copyright ©2023 Histogen. All Rights Reserved. Designed by TinyFrog Technologies.